O'Hanlon, Claire E <br/><br/>
A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.  [electronic resource] 

 -  Clinical therapeutics  Jul 2017 
 - 1276-1290 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1879-114X 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2017.05.348  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--economics<br/>Bone Density Conservation Agents--economics<br/>Cost-Benefit Analysis<br/>Denosumab--economics<br/>Female<br/>Humans<br/>Models, Theoretical<br/>Osteoporosis, Postmenopausal--drug therapy<br/>Osteoporotic Fractures--economics<br/>Parathyroid Hormone-Related Protein--economics<br/>Postmenopause<br/>Quality-Adjusted Life Years<br/>Risk<br/>Teriparatide--economics